Inclusion Criteria:

1. High-grade gliomas, metastatic brain tumors, and other brain tumors refractory to
conventional medical therapy.

2. Patient or family able and willing to give informed consent.

3. Subjects with metastatic cancer to the brain who have failed at least one
conventional therapy (surgery, stereotactic radio- surgery, chemotherapy, and/or
whole brain radiotherapy).

4. Four or fewer previously treated or untreated lesion(s) in the brain.

5. Tumor size ≤ 3.0 cm in largest diameter.

6. MR imaging is not contraindicated for the patient.

7. Lesion(s) are clearly defined on pre-therapy contrast enhanced MRI scans as
determined by the treating surgeon.

8. Able and willing to attend all study visits.

9. Karnofsky Performance Scale score >50.

10. Patients age 19 and older.

Exclusion Criteria:

1. Patients or family unwilling or unable to give written consent.

2. Patients who cannot physically fit in, or are too heavy for, the MRI scanner.

3. Patients with contra-indications to MRI imaging, such as, but not limited to, some
pacemakers or defibrillators, non- compatible aneurysm clips, shrapnel, or other
internal ferromagnetic objects.

4. Known sensitivity to gadolinium-DTPA, or glomerular filtration rate not compatible
with receiving gadolinium-DTPA.

5. Based on Treatment Planning Imaging (MR and/or CT):

- Lesions localized in the brain stem.

- Lesions less than 5mm from primary branches of cerebral vessels, venous
sinus, hypophysis or cranial nerves.

- Presence of more than 4 brain tumors at the time of enrollment.

- Medical issues which prohibit the patient from undergoing surgery (as
determined by the treating surgeon, anesthesiologist, IMPAC clinic, referring
physician).

- Positive pregnancy test for women of child-bearing age.